27241818|t|Group III/IV muscle afferents limit the intramuscular metabolic perturbation during whole body exercise in humans
27241818|a|The purpose of this study was to determine the role of group III/IV muscle afferents in limiting the endurance exercise - induced metabolic perturbation assayed in muscle biopsy samples taken from locomotor muscle. Lumbar intrathecal fentanyl was used to attenuate the central projection of μ-opioid receptor - sensitive locomotor muscle afferents during a 5 km cycling time trial. The findings suggest that the central projection of group III/IV muscle afferent feedback constrains voluntary neural ' drive ' to working locomotor muscle and limits the exercise - induced intramuscular metabolic perturbation. Therefore, the CNS might regulate the degree of metabolic perturbation within locomotor muscle and thereby limit peripheral fatigue. It appears that the group III/IV muscle afferents are an important neural link in this regulatory mechanism, which probably serves to protect locomotor muscle from the potentially severe functional impairment as a consequence of severe intramuscular metabolic disturbance. To investigate the role of metabo - and mechanosensitive group III/IV muscle afferents in limiting the intramuscular metabolic perturbation during whole body endurance exercise, eight subjects performed 5 km cycling time trials under control conditions (CTRL) and with lumbar intrathecal fentanyl impairing lower limb muscle afferent feedback (FENT). Vastus lateralis muscle biopsies were obtained before and immediately after exercise. Motoneuronal output was estimated through vastus lateralis surface electromyography (EMG). Exercise - induced changes in intramuscular metabolites were determine d using liquid and gas chromatography-mass spectrometry. Quadriceps fatigue was quantified by pre - to post - exercise changes in potentiated quadriceps twitch torque (ΔQTsingle) evoked by electrical femoral nerve stimulation. Although motoneuronal output was 21 ± 12% higher during FENT compared to CTRL (P < 0.05), time to complete the time trial was similar (∼8.8 min). Compared to CTRL, power output during FENT was 10 ± 4% higher in the first half of the time trial, but 11 ± 5% lower in the second half (both P < 0.01). The exercise - induced increase in intramuscular inorganic phosphate, H(+), adenosine diphosphate, lactate and phosphocreatine depletion was 55 ± 30, 62 ± 18, 129 ± 63, 47 ± 14 (P < 0.001) and 27 ± 14% (P < 0.01) greater in FENT than CTRL. ΔQTsingle was greater following FENT than CTRL (-52 ± 2 vs -31 ± 1%, P < 0.001) and this difference was positively correlated with the difference in inorganic phosphate (r(2) = 0.79; P < 0.01) and H(+) (r(2) = 0.92; P < 0.01). In conclusion, during whole body exercise, group III/IV muscle afferents provide feedback to the CNS which, in turn, constrains motoneuronal output to the active skeletal muscle. This regulatory mechanism limits the exercise - induced intramuscular metabolic perturbation, preventing an abnormal homeostatic challenge and excessive peripheral fatigue.
27241818	0	19	Group III/IV muscle	T017	UMLS:C0026845
27241818	20	29	afferents	T017	UMLS:C0027883
27241818	40	53	intramuscular	T082	UMLS:C0442117
27241818	84	94	whole body	T017	UMLS:C0444584
27241818	107	113	humans	T204	UMLS:C0086418
27241818	134	139	study	T062	UMLS:C2603343
27241818	147	156	determine	T058	UMLS:C1148554
27241818	169	188	group III/IV muscle	T017	UMLS:C0026845
27241818	189	198	afferents	T017	UMLS:C0027883
27241818	215	224	endurance	T033	UMLS:C0518031
27241818	267	274	assayed	T058	UMLS:C1510438
27241818	278	284	muscle	T017	UMLS:C0026845
27241818	285	299	biopsy samples	T017	UMLS:C0677862
27241818	311	320	locomotor	T038	UMLS:C0023946
27241818	321	327	muscle	T017	UMLS:C0026845
27241818	329	335	Lumbar	T082	UMLS:C0024090
27241818	336	347	intrathecal	T082	UMLS:C1370196
27241818	348	356	fentanyl	T103	UMLS:C0015846
27241818	383	390	central	T082	UMLS:C0205099
27241818	391	401	projection	T082	UMLS:C0348018
27241818	405	422	μ-opioid receptor	T103	UMLS:C0066908
27241818	435	444	locomotor	T038	UMLS:C0023946
27241818	445	451	muscle	T017	UMLS:C0026845
27241818	452	461	afferents	T017	UMLS:C0027883
27241818	489	494	trial	T062	UMLS:C0008976
27241818	500	508	findings	T033	UMLS:C0243095
27241818	526	533	central	T082	UMLS:C0205099
27241818	534	544	projection	T082	UMLS:C0348018
27241818	548	567	group III/IV muscle	T017	UMLS:C0026845
27241818	568	576	afferent	T017	UMLS:C0027883
27241818	577	585	feedback	T038	UMLS:C0678663
27241818	616	621	drive	T038	UMLS:C0013126
27241818	635	644	locomotor	T038	UMLS:C0023946
27241818	645	651	muscle	T017	UMLS:C0026845
27241818	686	699	intramuscular	T082	UMLS:C0442117
27241818	739	742	CNS	T022	UMLS:C3714787
27241818	749	757	regulate	T038	UMLS:C1327622
27241818	802	811	locomotor	T038	UMLS:C0023946
27241818	812	818	muscle	T017	UMLS:C0026845
27241818	837	847	peripheral	T082	UMLS:C0205100
27241818	848	855	fatigue	T033	UMLS:C0015672
27241818	877	896	group III/IV muscle	T017	UMLS:C0026845
27241818	897	906	afferents	T017	UMLS:C0027883
27241818	944	954	regulatory	T038	UMLS:C1327622
27241818	999	1008	locomotor	T038	UMLS:C0023946
27241818	1009	1015	muscle	T017	UMLS:C0026845
27241818	1093	1106	intramuscular	T082	UMLS:C0442117
27241818	1157	1163	metabo	T038	UMLS:C0025519
27241818	1187	1206	group III/IV muscle	T017	UMLS:C0026845
27241818	1207	1216	afferents	T017	UMLS:C0027883
27241818	1233	1246	intramuscular	T082	UMLS:C0442117
27241818	1277	1287	whole body	T017	UMLS:C0444584
27241818	1288	1297	endurance	T033	UMLS:C0518031
27241818	1351	1357	trials	T062	UMLS:C0008976
27241818	1358	1382	under control conditions	T033	UMLS:C2911690
27241818	1384	1388	CTRL	T033	UMLS:C2911690
27241818	1399	1405	lumbar	T082	UMLS:C0024090
27241818	1406	1417	intrathecal	T082	UMLS:C1370196
27241818	1418	1426	fentanyl	T103	UMLS:C0015846
27241818	1437	1447	lower limb	T017	UMLS:C0023216
27241818	1448	1454	muscle	T017	UMLS:C0026845
27241818	1455	1463	afferent	T017	UMLS:C0027883
27241818	1464	1472	feedback	T038	UMLS:C0678663
27241818	1474	1478	FENT	T038	UMLS:C0678663
27241818	1481	1497	Vastus lateralis	T017	UMLS:C0224444
27241818	1498	1504	muscle	T017	UMLS:C0026845
27241818	1505	1513	biopsies	T017	UMLS:C0677862
27241818	1567	1579	Motoneuronal	T017	UMLS:C0026609
27241818	1580	1600	output was estimated	T058	UMLS:C0204709
27241818	1609	1633	vastus lateralis surface	T017	UMLS:C0224444
27241818	1634	1650	electromyography	T058	UMLS:C0013839
27241818	1652	1655	EMG	T058	UMLS:C0013839
27241818	1688	1701	intramuscular	T082	UMLS:C0442117
27241818	1702	1713	metabolites	T103	UMLS:C0870883
27241818	1719	1728	determine	T058	UMLS:C1148554
27241818	1748	1784	gas chromatography-mass spectrometry	T058	UMLS:C1720784
27241818	1786	1796	Quadriceps	T017	UMLS:C0224440
27241818	1797	1804	fatigue	T033	UMLS:C0015672
27241818	1929	1942	femoral nerve	T017	UMLS:C0015808
27241818	1943	1954	stimulation	T058	UMLS:C1292856
27241818	1965	1977	motoneuronal	T017	UMLS:C0026609
27241818	2012	2016	FENT	T038	UMLS:C0678663
27241818	2029	2033	CTRL	T033	UMLS:C2911690
27241818	2072	2077	trial	T062	UMLS:C0008976
27241818	2114	2118	CTRL	T033	UMLS:C2911690
27241818	2140	2144	FENT	T038	UMLS:C0678663
27241818	2194	2199	trial	T062	UMLS:C0008976
27241818	2290	2303	intramuscular	T082	UMLS:C0442117
27241818	2304	2323	inorganic phosphate	T103	UMLS:C0031603
27241818	2325	2329	H(+)	T103	UMLS:C0033727
27241818	2331	2352	adenosine diphosphate	T103	UMLS:C0001459
27241818	2354	2361	lactate	T103	UMLS:C0022924
27241818	2366	2381	phosphocreatine	T103	UMLS:C0031634
27241818	2479	2483	FENT	T038	UMLS:C0678663
27241818	2489	2493	CTRL	T033	UMLS:C2911690
27241818	2527	2531	FENT	T038	UMLS:C0678663
27241818	2537	2541	CTRL	T033	UMLS:C2911690
27241818	2599	2609	positively	T033	UMLS:C1446409
27241818	2644	2663	inorganic phosphate	T103	UMLS:C0031603
27241818	2744	2754	whole body	T017	UMLS:C0444584
27241818	2765	2784	group III/IV muscle	T017	UMLS:C0026845
27241818	2785	2794	afferents	T017	UMLS:C0027883
27241818	2803	2811	feedback	T038	UMLS:C0678663
27241818	2819	2822	CNS	T022	UMLS:C3714787
27241818	2850	2862	motoneuronal	T017	UMLS:C0026609
27241818	2884	2899	skeletal muscle	T017	UMLS:C0242692
27241818	2906	2916	regulatory	T038	UMLS:C1327622
27241818	2957	2970	intramuscular	T082	UMLS:C0442117
27241818	3009	3029	abnormal homeostatic	T033	UMLS:C4022950
27241818	3030	3039	challenge	T058	UMLS:C0805586
27241818	3054	3064	peripheral	T082	UMLS:C0205100
27241818	3065	3072	fatigue	T033	UMLS:C0015672